RBCC Eagerly Following White House Plans to Counter Heroin/Painkiller Abuse

HENDERSON, Nev.--(BUSINESS WIRE)-- Rainbow Coral Corp. (RBCC) has taken note of the Obama Administration’s recent announcement of a new strategy to cut heroin and opiate use in several East Coast states. The company stands ready to assist and support Federal Medication Assisted Treatment (MAT) programs utilizing Naltrexone, an important prescription drug used in treatment of heroin and opiate addiction.

“We’re glad to see the Administration take this path that focuses on treatment rather than punishment,” said RBCC CEO Kimberly Palmer. “We believe RBCC and its partners have a great deal to contribute in these efforts and we look forward to assisting in any way we can. Naltrexone has been proven effective in treating these types of addictions and in helping people regain their lives.”

According to the Centers for Disease Control (CDC), heroin use has surged a staggering 63 percent over the past 10 years. This increase is closely tied to prescription opioid abuse, the CDC said, and 45 percent of those addicted to heroin are also addicted to prescription opioids.

Statistics reveal that 3.8 million people have tried heroin at least once in their lifetimes. Approximately 560,000 have used it in the last year, and 338,000 have used heroin in the last month.

Meanwhile, opioid prescription abuse affects nearly 1.9 million Americans and 4.5 million people use prescribed painkillers for non-medical purposes each month.

For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150819005341/en/

Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
President and CEO
[email protected]

Source: Rainbow Coral Corp.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Appy Pie's AI App Builder Granted U.S. Patent for Building Apps Through Natural Conversation
• Schneider Electric Showcases Technologies Advancing Water Resilience at WEFTEC 2026
• Elevest Capital Launches Fund 70, a 229 Unit High-Rise Multifamily Offering in Downtown Dallas